DOCSLIB.ORG

As a Candidate Gene Vav3 Locus and Identifies Idd18 Complexity of The

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
As a Candidate Gene Vav3 Locus and Identifies Idd18 Complexity of The Nonobese Diabetic Congenic Strain Analysis of Autoimmune Diabetes Reveals Genetic Complexity of the Idd18 Locus and Identifies Vav3 as a Candidate Gene This information is current as of September 24, 2021. Heather I. Fraser, Calliope A. Dendrou, Barry Healy, Daniel B. Rainbow, Sarah Howlett, Luc J. Smink, Simon Gregory, Charles A. Steward, John A. Todd, Laurence B. Peterson and Linda S. Wicker J Immunol 2010; 184:5075-5084; Prepublished online 2 Downloaded from April 2010; doi: 10.4049/jimmunol.0903734 http://www.jimmunol.org/content/184/9/5075 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2010/04/02/jimmunol.090373 Material 4.DC1 References This article cites 65 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/184/9/5075.full#ref-list-1 by guest on September 24, 2021 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Nonobese Diabetic Congenic Strain Analysis of Autoimmune Diabetes Reveals Genetic Complexity of the Idd18 Locus and Identifies Vav3 as a Candidate Gene Heather I. Fraser,* Calliope A. Dendrou,* Barry Healy,* Daniel B. Rainbow,* Sarah Howlett,* Luc J. Smink,* Simon Gregory,†,1 Charles A. Steward,† John A. Todd,* Laurence B. Peterson,‡,2 and Linda S. Wicker* Wehaveusedthepublicsequencingandannotationofthemousegenometodelimitthepreviouslyresolvedtype1diabetes(T1D)insulin- dependent diabetes (Idd)18 interval to a region on chromosome 3 that includes the immunologically relevant candidate gene, Vav3.To test the candidacy of Vav3, we developed a novel congenic strain that enabled the resolution of Idd18 to a 604-kb interval, designated Idd18.1, which contains only two annotated genes: the complete sequence of Vav3 and the last exon of the gene encoding NETRIN G1, Downloaded from Ntng1. Targeted sequencing of Idd18.1 in the NOD mouse strain revealed that allelic variation between NOD and C57BL/6J (B6) occurs in noncoding regions with 138 single nucleotide polymorphisms concentrated in the introns between exons 20 and 27 and immediately after the 39 untranslated region. We observed differential expression of VAV3 RNA transcripts in thymocytes when comparing congenic mouse strains with B6 or NOD alleles at Idd18.1. The T1D protection associated with B6 alleles of Idd18.1/Vav3 requires the presence of B6 protective alleles at Idd3, which are correlated with increased IL-2 production and regulatory T cell function. In the absence of B6 protective alleles at Idd3, we detected a second T1D protective B6 locus, Idd18.3, which is closely linked http://www.jimmunol.org/ to, but distinct from, Idd18.1. Therefore, genetic mapping, sequencing, and gene expression evidence indicate that alteration of VAV3 expression is an etiological factor in the development of autoimmune b-cell destruction in NOD mice. This study also demonstrates that a congenic strain mapping approach can isolate closely linked susceptibility genes. The Journal of Immunology, 2010, 184: 5075–5084. ype 1 diabetes (T1D) is a multifactorial autoimmune NOD mouse model of T1D (1) shares several features of etiology disease, and both environmental factors and genetic loci and genetics with human T1D and has been instrumental in the spread throughout the genome govern T1D onset. The identification of genes involved in T1D susceptibility and how T by guest on September 24, 2021 variants of these genes influence the immune system (2–7). Our laboratory has previously used a congenic strain mapping tech- *Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, Cambridge Institute for Medical Re- nique in the NOD mouse model, in which genome segments from search, University of Cambridge, Cambridge; †The Wellcome Trust Sanger Institute, a T1D-resistant mouse strain (B6 or C57BL/10J) are introgressed Wellcome Trust Genome Campus, Hinxton, United Kingdom; and ‡Department of Pharmacology, Merck Research Laboratories, Rahway, NJ 07065 into the susceptible NOD background, to localize T1D suscepti- bility loci (2, 8). Four of these loci, insulin-dependent diabetes 1Current address: Department of Medicine, The Center for Human Genetics, Duke University Medical Center, Durham, NC. (Idd)3, Idd10, Idd17, and Idd18, have been identified on mouse 2Current address: Hoffmann-La Roche, Inflammation Discovery, Nutley, NJ. chromosome three, and only Idd3 and Idd10 have proposed can- Received for publication November 19, 2009. Accepted for publication February 23, didate genes (9–12). The T1D protection associated with the 650- 2010. kb Idd3 region is most likely accounted for by the differential This work was supported by a Wellcome Trust four-year studentship (to H.I.F.), a joint expression between the NOD and B6 haplotypes of the IL-2 gene grant from the Juvenile Diabetes Research Foundation and theWellcome Trust (toL.S.W. (4), and the proposed candidate gene for the 950-kb Idd10 region and J.A.T.), and Wellcome Trust Strategic Award 079895 (to the Cambridge Institute for Medical Research). The resequencing of Idd18.1 in the NOD mouse strain was per- is Cd101 (12). formed at the Wellcome Trust Sanger Institute and was funded by Immune Tolerance The initial mapping of Idd18, which is closely linked and Network Contract AI 15416, which was sponsored by the National Institute of Allergy distal to Idd10, was performed by sequentially truncating the and Infectious Diseases, the National Institute of Diabetes and Digestive and Kidney Diseases, and Juvenile Diabetes Research Foundation International. The availability of Idd18 interval of a single homozygous B6-derived congenic NOD congenic mice through the Taconic Emerging Models Program has been supported segment that spanned Idd10 and Idd18. The resultant congenic by grants from the Merck Genome Research Institute, the National Institute of Allergy strains that had lost the B6 protective alleles at Idd18 had higher and Infectious Diseases, and the Juvenile Diabetes Research Foundation International. T1D frequencies compared with the nontruncated congenic Address correspondence and reprint requests to Prof. Linda S. Wicker, Juveniles Di- abetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, strains but were more protected from T1D than NOD mice as B6 Department of Medical Genetics, Cambridge Institute for Medical Research, Univer- alleles at Idd10 provided protection (13). The determination of sity of Cambridge, Cambridge CB2 0XY, U.K. E-mail address: linda.wicker@cimr. the recombination points of these novel congenic strains local- cam.ac.uk ized Idd18 to a genetic distance of 5.1 cM (13). Subsequently, The online version of this article contains supplemental material. a second congenic strain mapping strategy to positionally clone Abbreviations used in this paper: b2m, b2-microglobulin; BAC, bacterial artificial chro- mosome; DIL, Diabetes and Inflammation Laboratory; EST,expressed sequence tag; Idd, Idd18 was used, which exploited the enhanced T1D protection insulin-dependent diabetes; NIEHS, National Institute of Environmental Health Scien- observed when B6-derived alleles are present at both the Idd10/ ces; qPCR, real-time quantitative RT-PCR; SNP, single nucleotide polymorphism; T1D, 18 and Idd3 intervals (14). This second strategy sequentially type 1 diabetes; UTR, untranslated region. truncated the Idd18 interval of a bicongenic strain homozygous Copyright Ó 2010 by The American Association of Immunologists, Inc. 0022-1767/10/$16.00 for two B6-derived introgressed segments: one spanning Idd10 www.jimmunol.org/cgi/doi/10.4049/jimmunol.0903734 5076 Vav3 IS THE Idd18.1 AUTOIMMUNE DIABETES CANDIDATE GENE and Idd18 and a second spanning Idd3. Notably, the protection To develop the congenic mouse strains used to test the candidacy of Vav3 associated with Idd10 is not observed in the context of B6 alleles at as Idd18, NOD.B6 Idd3 Idd10 Idd18 (line 1538) congenic mice were Idd3 (10); therefore, when B6 alleles at Idd18 were eliminated in crossed with NOD mice. The progeny were intercrossed, and tail DNA was genotyped to identify mice with a recombination event proximal to Vav3, these congenic strains, the protection observed was equal to that which would produce a chromosome that was NOD at Vav3 and B6 for the provided by Idd3 alone. T1D frequencies of novel congenic strains remainder of the Idd18 interval. One mouse with a recombination event produced from this mapping effort reduced the Idd18 interval to proximal to Vav3 was backcrossed to NOD, and progeny heterozygous for a genetic distance of 2.04 cM (10). However, at that time in 2001, the desired recombination event—and that had retained the B6 allele at Idd3—were intercrossed to produce homozygous mice for line 2399.
Load more

Recommended publications
  • United States Patent ( 10 ) Patent No.: US 10,468,120 B2 Hakozaki Et Al
    US010468120B2 United States Patent ( 10 ) Patent No.: US 10,468,120 B2 Hakozaki et al. (45 ) Date of Patent : * Nov . 5 , 2019 (54 ) METHOD OF GENERATING A 2008/0280844 A1 * 11/2008 Lessnick C12Q 1/6886 HYPERPIGMENTATION CONDITION GENE 514/44 A 2009/0017080 A1 1/2009 Tanner et al. EXPRESSION SIGNATURE 2010/0189669 A1 * 7/2010 Hakozaki 424/60 2010/0292085 A1 * 11/2010 Lum GOIN 33/5067 (71 ) Applicant: The Procter & Gamble Company , 506/7 Cincinnati, OH (US ) 2011/0150798 A1 6/2011 Bacus 2011/0269852 A1 * 11/2011 McDaniel 514/789 ( 72 ) Inventors: Tomohiro Hakozaki, Cincinnati, OH 2012/0149773 A1 * 6/2012 Park A61K 31/203 (US ) ; Wenzhu Zhao , Mason , OH (US ) ; 514/552 Robert Lloyd Binder , Montgomery, 2013/0165470 A1 * 6/2013 Isfort A61K 31/439 OH (US ) ; Jun Xu , Mason , OH (US ) 514/289 (73 ) Assignee : The Procter & Gamble Company , FOREIGN PATENT DOCUMENTS Cincinnati , OH (US ) WO WO 2003/100557 12/2003 WO WO 2005/040416 5/2005 ( * ) Notice : Subject to any disclaimer, the term of this WO 2012011904 A1 1/2012 patent is extended or adjusted under 35 WO 2012116081 A2 8/2012 WO WO2012116081 8/2012 U.S.C. 154 ( b ) by 162 days . WO WO 2014/028572 2/2014 This patent is subject to a terminal dis claimer. OTHER PUBLICATIONS ( 21) Appl. No .: 13 /851,873 Affymetrix HGU133A 2.0 ( release 33 , submitted Oct. 30 , 2012 ) , Affymetrix.com . * Filed : Hakozaki et al. ( 2002 )British Journal of Dermatology 147.1 (2002 ) : ( 22 ) Mar. 27 , 2013 20-31 . * Aoki et al . (British Journal of Dermatology 156.6 (2007 ) : 1214 (65 ) Prior Publication Data 1223 ) .
    [Show full text]
  • Experimental Validation of the Regulated Expression of Large Numbers of Non-Coding Rnas from the Mouse Genome
    Downloaded from genome.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press Article Experimental validation of the regulated expression of large numbers of non-coding RNAs from the mouse genome Timothy Ravasi,1,4,5 Harukazu Suzuki,2,4 Ken C. Pang,1,3,4 Shintaro Katayama,2,4 Masaaki Furuno,2,4,6 Rie Okunishi,2 Shiro Fukuda,2 Kelin Ru,1 Martin C. Frith,1,2 M. Milena Gongora,1 Sean M. Grimmond,1 David A. Hume,1 Yoshihide Hayashizaki,2 and John S. Mattick1,7 1ARC Special Research Centre for Functional and Applied Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane QLD 4072, Australia; 2Laboratory for Genome Exploration Research Group, RIKEN Genomic Science Center, RIKEN Yokohama Institute, Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa, 230-0045, Japan; 3T Cell Laboratory, Ludwig Institute for Cancer Research, Austin & Repatriation Medical Centre, Heidelberg VIC 3084, Australia Recent large-scale analyses of mainly full-length cDNA libraries generated from a variety of mouse tissues indicated that almost half of all representative cloned sequences did not contain an apparent protein-coding sequence, and were putatively derived from non-protein-coding RNA (ncRNA) genes. However, many of these clones were singletons and the majority were unspliced, raising the possibility that they may be derived from genomic DNA or unprocessed pre-mRNA contamination during library construction, or alternatively represent nonspecific “transcriptional noise.” Here we show, using reverse transcriptase-dependent PCR, microarray, and Northern blot analyses, that many of these clones were derived from genuine transcripts of unknown function whose expression appears to be regulated.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Identification of Proteins That Are Differentially Expressed in Brains
    Journal of Proteomics 139 (2016) 103–121 Contents lists available at ScienceDirect Journal of Proteomics journal homepage: www.elsevier.com/locate/jprot Identification of proteins that are differentially expressed in brains with Alzheimer's disease using iTRAQ labeling and tandem mass spectrometry Benito Minjarez a,1, Karla Grisel Calderón-González a, Ma. Luz Valero Rustarazo b,2, María Esther Herrera-Aguirre a,MaríaLuisaLabra-Barriosa, Diego E. Rincon-Limas c,d, Manuel M. Sánchez del Pino b,3,RaulMenae,4, Juan Pedro Luna-Arias a,⁎ a Departamento de Biología Celular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav-IPN), Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Gustavo A. Madero, C.P. 07360 Ciudad de México, México b Unidad de Proteómica, Centro de Investigación Príncipe Felipe, C/Rambla del Saler 16, 46012 Valencia, España c Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA d Department of Neuroscience, McKnight Brain Institute, University of Florida, Gainesville, FL 32611, USA e Departamento de Fisiología, Biofísica y Neurociencias, Cinvestav-IPN, Av. Instituto Politécnico Nacional 2508, Col. San Pedro Zacatenco, Gustavo A. Madero, C.P. 07360 Ciudad de México, México article info abstract Article history: Alzheimer's disease is one of the leading causes of dementia in the elderly. It is considered the result of complex Received 5 November 2015 events involving both genetic and environmental factors. To gain further insights into this complexity, we Received in revised form 26 February 2016 quantitatively analyzed the proteome of cortex region of brains from patients diagnosed with Alzheimer's Accepted 11 March 2016 disease, using a bottom-up proteomics approach.
    [Show full text]
  • Anti-VAV3 (Aa 567-578) Polyclonal Antibody (DPABH-12442) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-VAV3 (aa 567-578) polyclonal antibody (DPABH-12442) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Antigen Description Exchange factor for GTP-binding proteins RhoA, RhoG and, to a lesser extent, Rac1. Binds physically to the nucleotide-free states of those GTPases. Plays an important role in angiogenesis. Its recruitement by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly. Immunogen Synthetic peptide: CSGEQGTLKLPEK, corresponding to internal sequence amino acids 567-578 of Human VAV3 Isotype IgG Source/Host Goat Species Reactivity Human Purification Immunogen affinity purified Conjugate Unconjugated Applications WB, IHC-P Format Liquid Size 50 μg Buffer pH: 7.40; Constituents: 0.5% BSA, Tris buffered saline Preservative 0.02% Sodium Azide Storage Store at 4°C or at -20°C for long term storage. GENE INFORMATION Gene Name VAV3 vav 3 guanine nucleotide exchange factor [ Homo sapiens ] Official Symbol VAV3 Synonyms VAV3; vav 3 guanine nucleotide exchange factor; vav 3 oncogene; guanine nucleotide exchange factor VAV3; VAV-3; FLJ40431; 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Entrez Gene ID 10451 Protein Refseq NP_001073343 UniProt ID Q9UKW4 Chromosome Location 1p13.3 Pathway B cell receptor signaling pathway; Cell death signalling via NRAGE, NRIF and NADE; Chemokine signaling pathway; Coregulation of Androgen receptor activity; EGFR1 Signaling Pathway; Function GTPase activator activity; Rac guanyl-nucleotide exchange factor activity; SH3/SH2 adaptor activity; epidermal growth factor receptor binding; guanyl-nucleotide exchange factor activity; metal ion binding; protein binding 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 2 © Creative Diagnostics All Rights Reserved.
    [Show full text]
  • Transcriptomic Profile of the Subiculum-Projecting VIP Gabaergic Neurons in the Mouse CA1 Hippocampus
    Brain Structure and Function (2019) 224:2269–2280 https://doi.org/10.1007/s00429-019-01883-z SHORT COMMUNICATION Transcriptomic profle of the subiculum‑projecting VIP GABAergic neurons in the mouse CA1 hippocampus Xiao Luo1,2 · Einer Muñoz‑Pino1,2 · Ruggiero Francavilla1,2 · Maxime Vallée3,4 · Arnaud Droit3 · Lisa Topolnik1,2 Received: 16 March 2018 / Accepted: 2 May 2019 / Published online: 16 May 2019 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract In cortical circuits, the vasoactive intestinal peptide (VIP+)-expressing GABAergic cells represent a heterogeneous but unique group of interneurons that is mainly specialized in network disinhibition. While the physiological properties and connectivity patterns have been elucidated in several types of VIP+ interneurons, little is known about the cell type-specifc molecular repertoires important for selective targeting of VIP+ cell types and understanding their functions. Using patch- sequencing approach, we analyzed the transcriptomic profle of anatomically identifed subiculum-projecting VIP+ GABAe- rgic neurons that reside in the mouse hippocampal CA1 area, express muscarinic receptor 2 and coordinate the hippocampo- subicular interactions via selective innervation of interneurons in the CA1 area and of interneurons and pyramidal cells in subiculum. We explored the VIP+ cell gene expression within major gene families including ion channels, neurotransmitter receptors, neuromodulators, cell adhesion and myelination molecules. Among others, a large variety of genes involved in neuromodulatory signaling, including acetylcholine (Chrna4), norepinephrin (Adrb1), dopamine (Drd1), serotonin (Htr1d), cannabinoid (Cnr1), opioid (Oprd1, Oprl1) and neuropeptide Y (Npy1r) receptors was detected in these cells. Many genes that were enriched in other local VIP+ cell types, including the interneuron-selective interneurons and the cholecystokinin- coexpressing basket cells, were detected in VIP+ subiculum-projecting cells.
    [Show full text]
  • Characterization of Glomerular Extracellular Matrix in Iga Nephropathy by Proteomic Analysis of Laser-Captured Microdissected Gl
    Paunas et al. BMC Nephrology (2019) 20:410 https://doi.org/10.1186/s12882-019-1598-1 RESEARCH ARTICLE Open Access Characterization of glomerular extracellular matrix in IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli Flavia Teodora Ioana Paunas1,2* , Kenneth Finne2, Sabine Leh2,3, Tarig Al-Hadi Osman2, Hans-Peter Marti2,4, Frode Berven5 and Bjørn Egil Vikse1,2 Abstract Background: IgA nephropathy (IgAN) involves mesangial matrix expansion, but the proteomic composition of this matrix is unknown. The present study aimed to characterize changes in extracellular matrix in IgAN. Methods: In the present study we used mass spectrometry-based proteomics in order to quantitatively compare protein abundance between glomeruli of patients with IgAN (n = 25) and controls with normal biopsy findings (n = 15). Results: Using a previously published paper by Lennon et al. and cross-referencing with the Matrisome database we identified 179 extracellular matrix proteins. In the comparison between IgAN and controls, IgAN glomeruli showed significantly higher abundance of extracellular matrix structural proteins (e.g periostin, vitronectin, and extracellular matrix protein 1) and extracellular matrix associated proteins (e.g. azurocidin, myeloperoxidase, neutrophil elastase, matrix metalloproteinase-9 and matrix metalloproteinase 2). Periostin (fold change 3.3) and azurocidin (3.0) had the strongest fold change between IgAN and controls; periostin was also higher in IgAN patients who progressed to ESRD as compared to patients who did not. Conclusion: IgAN is associated with widespread changes of the glomerular extracellular matrix proteome. Proteins important in glomerular sclerosis or inflammation seem to be most strongly increased and periostin might be an important marker of glomerular damage in IgAN.
    [Show full text]
  • Curcumin Is a Potent Modulator of Microglial Gene Expression And
    Karlstetter et al. Journal of Neuroinflammation 2011, 8:125 JOURNAL OF http://www.jneuroinflammation.com/content/8/1/125 NEUROINFLAMMATION RESEARCH Open Access Curcumin is a potent modulator of microglial gene expression and migration Marcus Karlstetter1†, Elena Lippe1†, Yana Walczak1†, Christoph Moehle2, Alexander Aslanidis1, Myriam Mirza1 and Thomas Langmann1* Abstract Background: Microglial cells are important effectors of the neuronal innate immune system with a major role in chronic neurodegenerative diseases. Curcumin, a major component of tumeric, alleviates pro-inflammatory activities of these cells by inhibiting nuclear factor kappa B (NFkB) signaling. To study the immuno-modulatory effects of curcumin on a transcriptomic level, DNA-microarray analyses were performed with resting and LPS-challenged microglial cells after short-term treatment with curcumin. Methods: Resting and LPS-activated BV-2 cells were stimulated with curcumin and genome-wide mRNA expression patterns were determined using DNA-microarrays. Selected qRT-PCR analyses were performed to confirm newly identified curcumin-regulated genes. The migration potential of microglial cells was determined with wound healing assays and transwell migration assays. Microglial neurotoxicity was estimated by morphological analyses and quantification of caspase 3/7 levels in 661W photoreceptors cultured in the presence of microglia-conditioned medium. Results: Curcumin treatment markedly changed the microglial transcriptome with 49 differentially expressed transcripts in a combined analysis of resting and activated microglial cells. Curcumin effectively triggered anti-inflammatory signals as shown by induced expression of Interleukin 4 and Peroxisome proliferator activated receptor a. Several novel curcumin- induced genes including Netrin G1, Delta-like 1, Platelet endothelial cell adhesion molecule 1,andPlasma cell endoplasmic reticulum protein 1, have been previously associated with adhesion and cell migration.
    [Show full text]
  • Chromosome Abnormalities in Two Patients with Features of Autosomal Dominant Robinow Syndrome
    ß 2007 Wiley-Liss, Inc. American Journal of Medical Genetics Part A 143A:1790–1795 (2007) Research Letter Chromosome Abnormalities in Two Patients With Features of Autosomal Dominant Robinow Syndrome Juliana F. Mazzeu,1 Ana Cristina Krepischi-Santos,1 Carla Rosenberg,1 Karoly Szuhai,2 Jeroen Knijnenburg,2 Janneke M.M. Weiss,3 Irina Kerkis,1 Zan Mustacchi,4 Guilherme Colin,5 Roˆmulo Mombach,6 Rita de Ca´ssia M. Pavanello,1 Paulo A. Otto,1 and Angela M. Vianna-Morgante1* 1Centro de Estudos do Genoma Humano, Departamento de Gene´tica e Biologia Evolutiva, Instituto de Biocieˆncias, Universidade de Sa˜o Paulo, Sa˜o Paulo, Brazil 2Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands 3Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands 4Hospital Infantil Darcy Vargas, Sa˜o Paulo, Brazil 5Departamento de Gene´tica Me´dica, Univille, Joinville, Brazil 6Centrinho Prefeito Luiz Gomes, Secretaria Municipal de Sau´de, Joinville, Brazil Received 13 April 2006; Accepted 13 December 2006 How to cite this article: Mazzeu JF, Krepischi-Santos AC, Rosenberg C, Szuhai K, Knijnenburg J, Weiss JMM, Kerkis I, Mustacchi Z, Colin G, Mombach R, Pavanello RM, Otto PA, Vianna-Morgante AM. 2007. Chromosome abnormalities in two patients with features of autosomal dominant Robinow syndrome. Am J Med Genet Part A 143A:1790–1795. To the Editor: Patient 1 Robinow syndrome [OMIM 180700] is characteriz- At age 3 4/12 years the girl was diagnosed as ed by fetal facies, mesomelic dwarfism, and hypo- affected by DRS (Fig. 1A). Detailed clinical examina- plastic genitalia.
    [Show full text]
  • Vav1 (D45G3) Rabbit Mab A
    Revision 1 C 0 2 - t Vav1 (D45G3) Rabbit mAb a e r o t S Orders: 877-616-CELL (2355) [email protected] Support: 877-678-TECH (8324) 7 5 Web: [email protected] 6 www.cellsignal.com 4 # 3 Trask Lane Danvers Massachusetts 01923 USA For Research Use Only. Not For Use In Diagnostic Procedures. Applications: Reactivity: Sensitivity: MW (kDa): Source/Isotype: UniProt ID: Entrez-Gene Id: WB, IP H Endogenous 95 Rabbit IgG P15498 7409 Product Usage Information Application Dilution Western Blotting 1:1000 Immunoprecipitation 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody. Specificity / Sensitivity Vav1 (D45G3) Rabbit mAb recognizes endogenous levels of total Vav1 protein. Species Reactivity: Human Species predicted to react based on 100% sequence homology: Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues in the carboxy terminus of human Vav1 protein. Background Vav proteins belong to the Dbl family of guanine nucleotide exchange factors (GEFs) for Rho/Rac small GTPases. The three identified mammalian Vav proteins (Vav1, Vav2 and Vav3) differ in their expression. Vav1 is expressed only in hematopoietic cells and is involved in the formation of the immune synapse. Vav2 and Vav3 are more ubiquitously expressed. Vav proteins contain the Dbl homology domain, which confers GEF activity, as well as protein interaction domains that allow them to function in pathways regulating actin cytoskeleton organization (reviewed in 1).
    [Show full text]
  • Datasheet Blank Template
    SAN TA C RUZ BI OTEC HNOL OG Y, INC . netrin G1 (H-4): sc-393665 BACKGROUND PRODUCT Netrin G1 and netrin G2, also referred to as laminet-1 and laminet-2, are Each vial contains 200 µg IgG 1 kappa light chain in 1.0 ml of PBS with membrane bound axon guidance molecules involved in synaptic formation and < 0.1% sodium azide and 0.1% gelatin. maintenance. They comprise a subgroup within the UNC-6/netrin family. Both genes have been associated with schizophrenia involving single nucleotide APPLICATIONS polymorphisms. They are both expressed in the brain but G1 is most predom - netrin G1 (H-4) is recommended for detection of netrin G1 of human origin inantly expressed in the thalamus and G2 is most predominantly expressed in by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), the cortex. These two proteins differ from classical netrins by their failure to immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell bind netrin receptors, the presence of a glycosyl phosphatidylinositol mem - lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- brane anchor, and the generation of multiple isoforms. Netrin G1 has at least 1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30- nine isoforms, all of which are expressed in adult brain. Isoforms G1a, c, d, 1:3000). and e are also expressed in fetal brain. G1c and G1d are the most highly ex- pressed netrin G1 isoforms. Netrin G1 is involved in NMDA receptor function Suitable for use as control antibody for netrin G1 siRNA (h): sc-72290, and may play a role in Rett syndrome (RTT), atypical autism, epilepsy and netrin G1 shRNA Plasmid (h): sc-72290-SH and netrin G1 shRNA (h) mental retardation.
    [Show full text]
  • Discovery of a Molecular Glue That Enhances Uprmt to Restore
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Discovery of a molecular glue that enhances UPRmt to restore proteostasis via TRKA-GRB2-EVI1-CRLS1 axis Authors: Li-Feng-Rong Qi1, 2 †, Cheng Qian1, †, Shuai Liu1, 2†, Chao Peng3, 4, Mu Zhang1, Peng Yang1, Ping Wu3, 4, Ping Li1 and Xiaojun Xu1, 2 * † These authors share joint first authorship Running title: Ginsenoside Rg3 reverses Parkinson’s disease model by enhancing mitochondrial UPR Affiliations: 1 State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 2 Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. 3. National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai 201210, China 4. Shanghai Science Research Center, Chinese Academy of Sciences, Shanghai, 201204, China. Corresponding author: Ping Li, State Key Laboratory of Natural Medicines, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Email: [email protected], Xiaojun Xu, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, China Pharmaceutical University, 210009, Nanjing, Jiangsu, China. Telephone number: +86-2583271203, E-mail: [email protected]. bioRxiv preprint doi: https://doi.org/10.1101/2021.02.17.431525; this version posted February 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
    [Show full text]